Welcome to our dedicated page for CODEXIS SEC filings (Ticker: CDXS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Codexis, Inc. filings document the company's public-company disclosures as a Nasdaq-listed biotechnology issuer focused on enzymatic solutions for therapeutics manufacturing. Recent 8-K reports furnish quarterly and annual operating results, financial-condition updates, business-update exhibits, and material event disclosures tied to organizational streamlining and the ECO Synthesis platform.
Proxy materials describe annual meeting voting, board classes and committee membership, director elections, executive compensation, and other governance matters. The filing record also identifies Codexis common stock, par value $0.0001 per share, trading under CDXS on the Nasdaq Global Select Market.
A holder of the issuer’s common stock has filed a notice of proposed sale under Rule 144 to sell 6,123 shares through Morgan Stanley Smith Barney Executive Financial Services on the NASDAQ, with an indicated aggregate market value of $10,409.10 and an approximate sale date of 01/07/2026.
The shares to be sold come from restricted stock units (RSUs) that vested and settled on 01/01/2026, when the holder acquired 17,450 shares as compensation for services rendered. The filing also notes that 90,324,383 shares of the issuer’s common stock were outstanding, providing context for the size of the planned sale.
Opaleye Management Inc. filed an amended insider transaction report for its holdings in Codexis, Inc. This Form 4/A corrects a clerical error for a November 26, 2025 trade that was originally reported as a stock acquisition and is now correctly shown as a disposition of Codexis common shares.
The report lists multiple indirect sales of Codexis common stock, par value $0.001 per share, through Opaleye, L.P. and a separately managed account on November 26, November 28 and December 1, 2025. Share blocks were sold at weighted average prices of $1.7413, $1.75 and $1.6675 per share, with actual trade prices within ranges of $1.7316–$1.75699, $1.73–$1.7715 and $1.65–$1.7101 as described in the footnotes. After the December 1, 2025 transactions, the report shows 9,955,000 Codexis shares indirectly held via Opaleye, L.P. and 179,989 shares via a managed account.
Codexis, Inc. director-affiliated investor Opaleye Management Inc. filed an amended ownership report detailing recent sales of Codexis common stock made through affiliated investment vehicles.
On 11/07/2025, Opaleye L.P. sold 296,682 shares and a separately managed account sold 10,000 shares, each at a weighted average price of $1.6968 per share. Additional sales occurred on 11/10/2025 of 205,000 and 3,318 shares at a weighted average price of $1.7347, and on 11/11/2025 of 535,000 and 13,211 shares at a weighted average price of $1.7994.
Following these transactions, Opaleye L.P. is reported as indirectly holding 11,508,318 shares, and the managed account 223,461 shares of Codexis common stock. The amendment corrects a clerical error so that the 11/07/2025 trades are properly coded as dispositions rather than acquisitions, with no other changes.
Codexis, Inc. (CDXS) reported an insider transaction by a director on a Form 4. On 11/21/2025, the reporting person sold 8,952 shares of common stock in an open-market transaction coded as "S" (sale).
The weighted average sale price was $1.5626 per share, with individual trades executed between $1.55 and $1.615. Following this sale, the reporting person beneficially owns 138,951 shares, held directly, which includes 40,983 restricted stock units.
Codexis, Inc. (CDXS) reported an equity award to its President and CEO, Alison Moore, on Form 4. On 11/13/2025 she received 85,000 shares of common stock in the form of restricted stock units, at a stated price of $0. These units vest in three equal annual installments on each anniversary of the grant date, provided she remains employed.
On the same date she was also granted a stock option for 500,000 shares of common stock at an exercise price of $1.63 per share, expiring on 11/13/2035. The option vests as to 25% of the shares on the first anniversary of the grant date and 1/48th of the original total each month thereafter, conditioned on continued employment. Following these transactions, she beneficially owns 254,332 shares, including 145,208 restricted stock units.
Codexis, Inc. (CDXS) chief scientific officer reports equity holdings in a beneficial ownership statement dated 11/07/2025. The officer directly owns 143,460 shares of Codexis common stock, including 53,266 restricted stock units that each convert into one share upon vesting. In addition, the officer holds multiple stock options covering shares of common stock with exercise prices ranging from $3.05 to $26.16 and expirations between 2030 and 2035. Some options are already fully vested and exercisable, while others vest over time based on specified schedules tied to dates from 2021 through 2026.
Codexis (CDXS): Opaleye Management Inc., as reporting person, disclosed open‑market sales of Codexis common stock on 11/12/2025. Transactions included 890,000 shares at $1.9372 and 165,000 shares at $1.962 through Opaleye, L.P., plus 27,459 shares at $1.9372 via a separately managed account. The prices are weighted averages; the shares were sold in multiple trades within disclosed ranges.
Following the reported transactions, beneficial ownership reported as indirect included 10,453,318 shares by Opaleye, L.P. and 196,012 shares by the managed account. The pricing footnotes state sales occurred across ranges of $1.9005–$1.9905 and $1.935–$2.0035, with full trade details available upon request.
Codexis (CDXS) reported a Form 4 for director Raymond De Vre. On 11/11/2025, he sold 1,413 shares of common stock at $1.74 per share, coded “S.” The filing notes the sale was effected to cover tax liability from the vesting and release of restricted stock units. After the transaction, he beneficially owned 87,416 shares, which includes 72,880 restricted stock units. Ownership is reported as direct.
Codexis, Inc. (CDXS) reported an insider open‑market purchase. Director Stephen G. Dilly bought 50,000 shares of common stock on 11/11/2025 at a weighted average price of $1.8473, executed in multiple trades ranging from $1.7550 to $1.90.
After this transaction, he beneficially owns 727,053 shares, held directly. This total includes 2,000 shares acquired under the Employee Stock Purchase Plan on May 10, 2025 and 2,000 shares acquired on Nov 10, 2025.
Opaleye Management Inc., a director of Codexis (CDXS), reported open‑market sales of common stock. Transactions occurred on 11/07/2025, 11/10/2025, and 11/11/2025 at weighted average prices of $1.6968, $1.7347, and $1.7994, respectively.
Reported sale sizes included 296,682 and 10,000 shares on 11/07/2025; 205,000 and 3,318 shares on 11/10/2025; and 535,000 and 13,211 shares on 11/11/2025. Following these transactions, beneficial ownership was 11,508,318 shares indirectly through Opaleye, L.P., and 223,461 shares indirectly through a managed account.